RVD Plus Transplantation Delayed Progression in Myeloma
Combined treatment with lenalidomide, bortezomib, and dexamethasone plus transplantation significantly delayed progression in patients with multiple myeloma.
Relapsed, Refractory Myeloma Has Indirect Societal Costs
Patients with relapsed or refractory multiple myeloma experienced significant indirect social costs from their disease, in addition to the direct costs.
‘VCD-Lite’ Viable Option for Older, Toxicity-Vulnerable Myeloma Patients
Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma.
FDA Approves Maintenance Lenalidomide for Multiple Myeloma
The FDA has expanded the approval of lenalidomide to include its use as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
Emerging Therapies in Multiple Myeloma
In this interview we discuss the latest therapy developments in the treatment of multiple myeloma.
No Association Between Response Rates and Survival in Newly Diagnosed Multiple Myeloma
There was no association between conventional response outcomes, such as complete response or very good partial response, and survival in patients with newly diagnosed multiple myeloma.
ASCT Standard for Newly Diagnosed Young Myeloma Patients
Upfront treatment with melphalan and ASCT should be the standard treatment approach for younger patients with newly diagnosed multiple myeloma.
QOL of Multiple Myeloma Patients Receiving Maintenance Therapy
This interview examines a study that looked at the health-related quality of life of multiple myeloma patients in a real-world setting who underwent maintenance therapy after autologous stem cell transplant.
New Standard of Care in Relapsed, Refractory Myeloma?
In this video, Antonio Palumbo, MD, discusses results of the CASTOR trial, which studied daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
This slide show on multiple myeloma includes images of bone marrow aspirates revealing sheets of tumor cells and organs with amyloid deposits and disease involvement.
By clicking Accept, you agree to become a member of the UBM Medica Community.